Fresh analysis reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Research printed in a prominent health publication points out that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People using these medications must be aware of the potential of fast weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment weight within about 18 months.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, compared the results of the injectable medications with older methods.
The team point out that individuals who lose weight through diet and exercise typically see a less rapid weight regain—around 0.1 kg a month—once they finish.
Understanding the Fast Regain
Doctors propose the mechanism of the jabs explains the amplified weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' leads to hunger is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, given the significant potential of weight regain, the treatment might need to be life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "underscore the long-term nature of obesity," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have stopped the jabs explain a powerful return of cravings.
"I experienced a switch activating and you're instantly starving," described a patient.
This challenge is compounded if users have not developed lasting dietary or behavioural changes during therapy.
Widespread Interest
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on integrated lifestyle support.
